Why Consumers aren’t Buying “High Cost-of-Developing Drugs” Argument
The Economist recently published an article on the government of India denying Novartis the patent for its cancer drug, Glivec (in the U.S. marketed as Gleevec). In reading the reader comments, it is obvious that a sense of fairness violation was perceived by readers who felt that the government was correct in denying Novartis this [...]
Source: NAKEDMEDICINE.COM - Category: Health Medicine and Bioethics Commentators Authors: Jane Chin Tags: Affordable Healthcare Business of Medicine Drug Companies Politics in Medicine Science and Research Source Type: blogs
More News: Cancer | Cancer & Oncology | Gleevec | Government | Health | Health Medicine & Bioethics Commentators | Politics | Science